| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2005-1581
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2005-1587
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2220-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2202-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-14248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-264
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-262 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate |
2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b587451221e9ac6c89b44c19b6ece551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b6a43854fbab306e35dd4fb1898276f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28585351e3a3a7c0b44da9a170ad7f6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e3aa7b2ee554e71380d1d888de3d4c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76dfe6ddcaf368d7441fef3199f7c4fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f28274aaa650ae9b19271763e9e60b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_705de4b96d8d1a61d2f7ca5670233efc |
| publicationDate |
2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2017252458-A1 |
| titleOfInvention |
Infusion set with components comprising a polymeric sorbent to reduce the concentration of m-cresol in insulin |
| abstract |
An insulin infusion set (IIS) device with one or more features designed to achieve longevity in a patients continuous subcutaneous insulin infusion (CSII) site viability. One exemplary feature is an adsorbent material configured to adsorb phenolic excipients (e.g., m-cresol or other preservatives) from the insulin formulation. The adsorbent material may be positioned along a fluid pathway specifically designed to increase and/or extend exposure between the insulin formulation and the adsorbent material. Another exemplary feature is a medicament configured to reduce the patients inflammation or slow the progression of the patients inflammatory response. Yet another exemplary feature is a diffusive catheter configured to deliver the insulin formulation in a diffuse manner. |
| priorityDate |
2016-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |